Puerto Rico Health & Insurance Conference 2019

Panel III. A Brave New World. Rx Post Rebate Revolution, Trump's Blue Print & the Implications for Pharmaceutical Coverage in the US Mainland versus Puerto Rico

Moderator: Carolyn Rodriguez PharmD; EVP Pharmacy MCS

Panelists: Marileny Lugo RPh; COO MC-21 Corp Jason Borschow; President and CEO, Abarca Health, LLC Martty Martinez PharmD; President and Pharmacy Officer, PharmPix Corp.




Background and Context

- On May 2018, the U.S Department of Health and Human Services (HHS) release the Blue Print
 - Detailed diagnosis of US Drug Pricing (What is the problem?)
 - Comprehensive plan with the intention to bring drug pricing down
 - 4 key strategic areas:
 - Improved competition
 - Better Negotiation
 - Incentives to lower prices
 - Lowering out of pocket
 - Phases: Immediate actions and others that requires industry feedback

What is the problem

The U.S. Pharmacy Distribution and Reimbursement System



HHS Proposed Rule for Rebates

1. Revision: to remove the safe harbor protection of the manufacturers rebates in relation to the Federal anti-kickback statute

2. Addition: add a new safe harbor to protect rebates discounts directly to patients at the point of sale

3. Addition: add a new safe harbor protection for fixed fees services arrangements between Manufacturers and PBM's

Panelists Discussion

- What are the implications of this vision to PBM's and Health Plans as your clients?
- HHS published a proposed rule on how rebates should be managed:
 - How will this impact the PBM model in terms of pharmaceutical negotiations and the way PBM help Plans Sponsors to reduce drug cost. How would this post-rebate model work?
 - Will brand drug prices really come down?
- How do you see the future of pharmacy administration and Rx coverage being impacted and if beneficiaries will really benefit from these changes? Will this be different in Puerto Rico vs the US mainland?













www.camarapr.org

#tucamaraenaccion